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Abstract Haemoglobin concentration ([Hb]), reticulocyte
percentage (retic%) and OFFhr score are well-implemented
screening tools to determine potential recombinant human
erythropoietin (rHuEpo) abuse in athletes. Recently, the
International Cycling Union implemented the OFFz score and
the Hbz score in their anti-doping testing programme. The aim
of this study is to evaluate the sensitivity of these indirect
screening methods. Twenty-four human subjects divided into
three groups with eight subjects each (G1; G2 and G3) were
injected with rHuEpo. G1 and G2 received rHuEpo for a
4-week period with 2 weeks of ‘‘boosting’’ followed by
2 weeks of ‘‘maintenance’’ and a wash-out period of 3 weeks.
G3 received rHuEpo for a 10-week period (boost = 3 weeks;
maintenance = 7 weeks; wash out = 1 week). Three, seven
and eight of the 24 volunteers exceeded the cut-off limits for
OFFhr score, [Hb] and retic%, respectively. One subject from
G1, nobody from G2, and seven subjects from G3 exceeded
the cut-off limit for Hbz score. In total, ten subjects exceeded
the cut-off limit for the OFFz score; two subjects from G1, two
subjects from G2 and six subjects from G3. In total, indirect
screening methods were able to indicate rHuEpo injections in
58% of subjects. However, 42% of our rHuEpo-injected
subjects were not detected. It should be emphasised that the
test frequency in real world anti-doping is far less than the
present study, and hence the detection rate will be lower.
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Introduction
The misuse of rHuEpo was banned by the International
Olympic Committee in 1990 (Robinson et al. 2006), but its
detection is not easy. Different methods, including direct
blood screening and urine tests, are today available for the
screening/detection of rHuEpo abuse (Lasne and de
Ceaurriz 2000). However, the urine test has been recently
criticised because of the possibility of false-positive tests
(Beullens et al. 2006), false-negative tests (Lundby et al.
2008a), very short detection periods (Ashenden et al. 2006;
Lundby et al. 2008a), basic shifts in EPO isoelectric pat-
terns (Lamon et al. 2009), and because the test is costly in
use (Gore et al. 2003).
More recently, indirect methods to determine potential
rHuEpo have been developed and led to the implementa-
tion of the so-called Blood Passport (Cazzola 2000), which
is based on the measurements of haemoglobin concentra-
tion ([Hb]) and the proportion of immature red blood cells
[the percentage of reticulocytes (retic%)], and the derived
OFFhr score, Hbz score and OFFz score (Sharpe et al. 2006).
The overall rationale for the Blood Passport is that if a
value deviates from preceding values by a certain magni-
tude, this may be indicative of doping (Sharpe et al. 2006).
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Recently, both the International Ski Federation (FIS) and
the International Cycling Union (UCI) implemented the
Blood Passport, in their efforts to limit doping.
The presently utilised algorithms used in anti-doping
settings were developed based on the human subjects
injected with rHuEpo three times per week for a total of up
to 8 weeks (40–50 IU/kg body weight (BW) three times per
week for 3 weeks and then 18–20 IU/kg BW three times per
week for 4–5 weeks) (Sharpe et al. 2006). When developing
the Hbz score and OFFz score, Sharpe et al. (2006) were able
to demonstrate rHuEpo use in all of their 37 rHuEpo-
injected subjects. Subsequently, however, it was demon-
strated that after a boosting period with frequent injections a
single rHuEpo injection per week of 60–65 IU/kg BW (and
hence not very different from the dose used by Sharpe et al.)
is sufficient to increase exercise performance (Lundby et al.
2008a, b; Thomsen et al. 2007). Therefore, the objective
with the present study was to test the effectiveness and
sensitivity of the current Blood Passport to indicate the use
of rHuEpo in human subjects injected with rHuEpo in
amounts sufficient to increase performance. In total, 400
blood samples obtained from 24 subjects receiving rHuEpo
injections were screened, with a total of 13–19 individual
samples. We hypothesised that the lower injection fre-
quency used in the present study when compared with those
performed in the past would lead to a reduced detection rate.
Methods
Subjects
Twenty-four healthy male volunteers (university students,
moderately trained) divided into three groups with eight
subjects each (G1; G2 and G3) participated in this study.
Subjects (G1 23 ± 3 years (±SD), 181 ± 7 cm, 77 ± 5 kg;
G2: 25 ± 4 years, 183 ± 6 cm, 79 ± 7 kg; G3: 27 ± 7
years, 180 ± 4 cm, 83 ± 7 kg) did not take part in any kind
of organised sports or training during the study period.
The study was approved by the local ethics committee
of the communities of Copenhagen and Frederiksberg,
Denmark (KF 01 269 637) and conformed to the Decla-
ration of Helsinki. All subjects were fully informed orally
and in writing about risks and discomforts associated with
the experiment before giving their written informed con-
sent to participate. From the groups G1 and G3 perfor-
mance data have been published elsewhere (Lundby et al.
2008a, b; Thomsen et al. 2007).
Protocol
Both G1 and G2 received rHuEpo (Epoetin b; 5,000 IU,
NeoRecormon, Roche, Mannheim, Germany) injections
(65 ± 5 IU/kg BW) for a 4-week period with 2 weeks of
‘‘boosting’’ followed by 2 weeks of ‘‘maintenance’’. Dur-
ing the boosting period, the volunteers were injected with
rHuEpo every second day (4 injections/week) and during
the maintenance period they had one weekly injection. The
injection period was followed by a 3-week long wash-out
period where no further injections were given, but blood
sampling continued. G3 received rHuEpo injections
(5,000 IU; 60 ± 4 IU/kg BW) for a 10-week period with
3 weeks of boosting (rHuEpo injections every second day
for the first 2 weeks and rHuEpo injections on three con-
secutive days in the third week) followed by 7 weeks of
‘‘maintenance’’ (one injection per week) and a wash-out
period of 1 week. rHuEpo injections (in 0.3-ml saline)
were given subcutaneously in the upper arm and all
injections were given between 8:00 and 10:00 a.m. in the
seated position. In G3, all subjects received iron at 100 mg/
day orally. This treatment was started 2 weeks prior to
rHuEpo injections and was maintained throughout the
entire study period.
Blood samples were collected (BD Vacuutainer blood
collection tubes containing heparin) in the seated position
from an antecubital vein before, during and after rHuEpo
injections on days 2, 4, 6, 10, 12, 14, 21, 28, 35, 42, 49 in
G1 (baseline measurements in G1 were obtained twice on
individual specific days, 3–4 days apart and on average
12 days before the first rHuEpo injection); on days -13,
-12, 1, 4, 8, 16, 21, 23, 25, 28, 30, 32, 35, 37, 39, 42, 44,
and 46 in G2 and on days -35, -21, -14, -7, 1, 3, 5, 7,
9, 11, 15, 22, 28, 36, 43, 50, 57, 64, and 71 in G3. The
venous blood samples were analysed on a Sysmex Roche
XE-2100 (Sysmex Europe, Norderstedt, Germany) ana-
lyser for G1 and G2 measurements and using a Sysmex
R-3000 (Sysmex Europe, Norderstedt, Germany) for G3
measurements.
Measured/calculated parameters
[Hb] (g/dl) and retic% were directly measured. To calcu-
late the OFFhr score (Gore et al. 2003), an algorithm based
on [Hb] and retic%, the following formula was used:
OFFhr score ¼ Hb½  ðg/LÞ  60
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
retic%
p
z Scores were derived from the following formulas:
OFFz score ¼ ðOFFcurrent  OFFmeanÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðr2ð1 þ 1=nÞÞ
p
Hbz score ¼ ðHbcurrent  HbmeanÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðr2ð1 þ 1=nÞÞ
p
where n denotes the number of previous blood samples
taken to obtain the mean, and r2 denotes the within-subject
variance including the between-day variance. For Hbz score,
r2 = 39.86 and for OFFz score r
2 = 75.90. Hbmean and
OFFmean are the average of the values ([Hb] or OFFhr score)
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of all samples taken prior to the current sample (Sharpe
et al. 2006).
Sensitivities were calculated as percentage of samples
exceeding the different cut-off limits during boosting,
maintenance and wash-out periods.
Cut-off limits
The World Anti-Doping Agency (WADA) has imple-
mented an upper cut-off limit for the [Hb] of 17 g/dl and
UCI assesses a rider to be suspicious of doping if the retic%
\0.2% or [2.4% (§4, 13.1.063 and 13.1.063 bis, part 13,
UCI cycling regulations, version 19.01.09).
UCI uses the OFFhr score to ban male athletes from
competition (Sharpe et al. 2006) if a cut-off limit of 133 is
exceeded (§4, 13.1.062, part 13, UCI cycling regulations,
version 19.01.2009) allowing 1 in 1,000 false-positive test.
According to FIS anti-doping rules (FIS.B.4.2, FIS anti-
doping rules, Edition 2009) and following Sharpe et al.
(2006) recommendations, an athlete with an Hbz score or an
OFFz score C3.09 will be subject to a no-start sanction of
14 days. This cut-off limit corresponds to 1 in 1,000 false-
positive test.
Results and discussion
In this study, we have evaluated effectiveness and sensi-
tivity of the following haematological models/parameters;
[Hb], retic%, OFFhr score, Hbz score and OFFz score to indi-
cate rHuEpo doping. The main finding was that 42% of the
subjects were not identified as rHuEpo doped. Because test
frequency in the real world is much lower than in our
study, this demonstrates that using haematological
screening methods in an attempt to detect low-dose rHu-
Epo doping is a very difficult task.
7 of the 24 volunteers exceeded the cut-off limit for
[Hb]; 1 from G1, 3 from G2 and 3 from G3 (Fig. 1b;
Table 1). In total, eight volunteers exceeded the cut-off
limit for retic%; two from G1, two from G2 and four from
G3 (Fig. 1c; Table 1). The cut-off limit for retic% was
especially sensitive during the boosting period where eight
subjects exceeded the cut off, resulting in a sensitivity of
12.0% (Fig. 1c; Table 1). The [Hb] cut off limit was
mostly exceeded during the maintenance and wash-out
period (sensitivity 16.2 and 15.6%, respectively), however,
one subject exceeded the cut off on one occasion during the
pre-period (Table 1).
In total, three of the volunteers exceeded the cut-off
limit for the OFFhr score (OFFhr score C133) during the
wash-out period (nobody from G1, 2 subjects from G2 and
1 subject from G3, Fig. 1a; Table 1). In the wash-out
period, the sensitivity of the OFFhr score was 5.6%. One
subject from G1, none from G2, and seven subjects from
G3 exceeded the cut-off limit for the Hbz score (z value
C3.09) with most subjects exceeding the cut off during the
maintenance period (Fig. 2b; Table 1). The sensitivity was
12.3% in the maintenance period.
In total, ten subjects exceeded the cut-off limit for the
OFFz score; two subjects from G1, two subjects from G2 and
six persons from G3. These subjects exceeded the cut off
during the maintenance and wash-out periods (Fig. 2a;
Table 1). Based on the number of subjects found positive
using the OFFz score (10 out of 24 subjects found positive), it
can be concluded that the addition of the OFFz score is an
improvement to the current testing programme, as the pre-
viously well-implemented parameter of retic% only caught
eight subjects. The overall sensitivity for the OFFz score was
11.1% during the wash-out period when including G1, G2
and G3, but the sensitivity was particularly high in G3,
where a sensitivity of 60% was found (material = 5 sam-
ples). In total, indirect screening methods were able to
indicate potential rHuEpo doping in 58% of subjects.
The main difference between the present study and the
ones used to construct the algorithms for the Blood Pass-
port is the injection frequency, and not the dosage of
injection, which was quite similar. In the previous studies,
subjects were injected with rHuEpo three times weekly
during the maintenance periods (Sharpe et al. 2006),
whereas we made use of a single injection throughout the
maintenance periods. Despite the lower injection frequency
in the maintenance period, total haemoglobin mass was
increased (Lundby et al. 2008a, 2007) and accordingly also
exercise performance was increased (Lundby et al. 2008a;
Thomsen et al. 2007), and hence justifies testing this
procedure for anti-doping countermeasures. It may be
speculated that a reduction in the concentration of the
weekly rHuEpo injections (so-called micro doses) may still
improve performance, and at the same time even further
decrease the sensitivity of the Blood Passport.
Overall, we were able to identify more subjects in
G3 (7 subjects) compared with G1 (3 subjects) and G2
(4 subjects). This demonstrates that the success using
haematological screening methods is highly dependent on
the individual athlete’s injection regime. Not surprisingly,
a longer boosting phase and maintenance period made it
easier to indicate rHuEpo use.
It is worth mentioning that the detection periods for
some subjects in our study were very short and can be
illustrated as follows: one subject from G2 exceeded the
cut-off limit for the OFFz score, but not any of the other cut-
off limits. Furthermore, this subject only exceeded the cut
off on a single day, day 42, in the wash-out period and the
subject did not exceed the cut off on either days 39 or 44.
In G3, it was shown that the Hbz score was in particular
effective late in the maintenance period as seven out of
Eur J Appl Physiol (2010) 109:537–543 539
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eight subjects here were identified and the sensitivity was
26% (Table 1). It should be noted that in G3 the wash-out
period was very short. During most of the maintenance
period in these subjects, retic% had decreased to pre-study
values, and remained at this level also in the wash-out
period. It cannot be ruled out, however, that changes would
have occurred later in the wash-out period due to changes
in erythropoietic activity.
We found an increased effectiveness to indicate rHuEpo
abuse when the different haematological models/parame-
ters were combined. For example, the retic% was very
useful during the boosting period, whereas during the
maintenance period the OFFz score and Hbz score were the
most effective measures, and in the wash-out period
the [Hb] and the OFFz score caught the highest number of
subjects. It must be kept in mind however that our study
Fig. 1 Individual changes in a OFFhr score, b haemoglobin concen-
tration, and c percentage of reticulocytes in all 24 subjects during the
study period. The three figures to the left represent G1 and G2 and the
three figures to the right represent G3. Each line corresponds to one
subject and each symbol corresponds to the same subject in all figures.
For G1, the baseline measurement is an average value obtained from
two samples taken on an average 12 days before the first rHuEpo
injection. The horizontal dashed lines in the OFFhr score graph
represent the cut-off limit 133, the horizontal dashed line in the
haemoglobin graph represents the upper cut off of 17 g/dl, and the
upper and lower horizontal dashed lines in the reticulocyte graph
represent the 2.4 and 0.2% cut off, respectively
540 Eur J Appl Physiol (2010) 109:537–543
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was conducted in a defined period of time, and with the
obtaining of serial blood drawings.
To calculate OFFz scores and Hbz scores, we have used two
default values of r2. For us, it is impossible to state whe-
ther or not an individually calculated value of r2 for each
subject would increase the detection rate, as the detection
rate for some subjects would be increased, but decreased
for other subjects depending on the variation in the baseline
samples. From our data, it is not possible to calculate a
suitable value of r2 for each athlete as this according to
Sharpe et al. (2006) would require at least six samples for
the baseline reading and possibly considerably more. We
only have two baseline samples from each subject in G1
and G2, and four baseline samples from subjects in G3.
However, if more baseline samples were available, it
would be rather easy to calculate individual values of r2
using the Athlete’s Biological Passport Management tool.
It has been proposed that the sensitivity may be
increased if the different indirect screening methods are
combined and used alongside the other test procedures,
such as urine tests or the recently proposed implementation
of total Hb mass (Eastwood et al. 2008). We should
mention, however, that a recent study demonstrated the
failure of total Hb mass to be a reliable marker for rHuEpo
use (Lundby and Robach 2009). A limitation to the present
study is that moderately trained university students do not
represent the target population. It has been shown that elite
athletes due to training and competitions are characterised
by heavy changes in [Hb] and retic% (Mørkeberg et al.
2009) (for a recent review, please see Banfi (2008)) and
such changes of course need to be considered when eval-
uating a potential change in blood profile. Finally, it should
also be kept in mind that Epo is known to have other
physiological effects than those related to haematology,
and some of these have been proposed to increase exercise
performance. In an attempt to unravel the contribution of
such mechanisms, we tested exercise performance in Epo-
treated subjects before and after isovolumic haemodilution
(Lundby et al. 2008b). In these studies, exercise perfor-
mance was similar in both trials and we concluded that the
effects of Epo on exercise performance are mainly medi-
ated through altered oxygen carrying capacities. Reported
psychological effects of Epo (Ninot et al. 2006) may,
however, be of higher importance during sub-maximal
exercise intensities and it remains an open question whe-
ther Epo alters sub-maximal exercise capacity by other
means than increasing the oxygen carrying capacity.
In conclusion, we were only able to indicate rHuEpo use
in 58% of our 24 subjects receiving rHuEpo injections over
a period of 0–10 weeks using the Blood Passport approach,
even though the subjects were intensively tested before,
during and after rHuEpo injections (13–19 individual blood
samples). However, the Blood Passport is an improvement
to current anti-doping measures as the z scores showed
higher effectiveness than any other previously implemented
blood models/parameters. At the same time, our study
demonstrates the OFFhr score is ineffective in anti-doping
work, and we would suggest this parameter to be excluded.
It must also be emphasised that the implementation of the
Blood Passport does not guarantee a doping-free sport as
our study represents the ‘‘ideal world’’ with frequent testing.
In the ‘‘real world’’, anti-doping agencies will conduct far
fewer doping tests and athletes might inject lower Epo
doses, which is crucial because of the limited detection
intervals (Ashenden et al. 2006). The difference in our study
Table 1 Number of subjects exceeding various cut offs for haemo-
globin concentration (g/dl); retic%, percentage of reticulocytes;
OFFhr score, OFFz score and Hbz score (points)
Method/
group
Pre Boost Maint. Wash out Total
[Hb] C 17.0 g/dl
G1 – – 1 (6.3) 1 (4.8) 1/8 (2.4)
G2 1 (6.3) – 1 (10.0) 3 (18.8) 3/8 (12.5)
G3 – 1 (1.8) 3 (21.6) 1 (20.0)a 3/8 (11.7)
Total 1 (1.6) 1 (0.8) 5 (16.2) 5 (15.6) 7/24 (9.9)
%retic. C 2.4%
G1 – 2 (8.7) – – 2/8 (4.8)
G2 – 2 (8.3) 1 (2.5%) – 2/8 (2.3)
G3 1 (3.4) 4 (16.4) – –a 4/8 (8.2)
Total 1 (1.6) 8 (12.0) 1 (0.9) – 8/24 (5.0)
%retic. B 0.2%
G1, G2, G3 – – – – –
OFFhr C 133
G1 – – – – –
G2 – – – 2 (6.3) 2/8 (3.1)
G3 – – – 1 (20.0)a 1/8 (0.9)
Total – – – 3 (5.6) 3/24 (1.6)
OFFz score C 3.09
G1 – 2 (12.5) 2 (14.3) 2/8 (6.0)
G2 – – 2 (6.3) 2/8 (3.1)
G3 – -5 (16%) 3 (60%)a 6/8 (10)
Total – 7 (9.4) 7 (11.1) 10/24 (6.2)
Hbz score C 3.09
G1 1 (2.2) 1 (6.3) 1 (4.8) 1/8 (3.6)
G2 – – – –
G3 1 (1.8) 7 (26.0) 2 (40.0%)a 7/8 (14.5)
Total 2 (0.8) 8 (12.3) 3 (2.2) 8/24 (5.0)
The numbers in parentheses denotes the sensitivity (percentage of
samples within the pre, boost, maintenance or wash-out period
exceeding the various cut offs)
Total denotes the number of subjects in each group exceeding the cut
off and the numbers in parentheses denotes the sensitivity post the
first rHuEpo injection
a Samples missing for three subjects
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and the one presently implemented by UCI and FIS raises
the question on how many samples for each individual are
necessary to be collected during the season to have a
meaningful testing programme? It should also be remem-
bered that performance gains are observed even with rela-
tively small changes in [Hb] (Calbet et al. 2006).
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